ABSTRACT
Introduction: In India, obesity affects >135 million and leads to nearly 5.8 million deaths per
year. Some of the unmet need in the management of obesity can be fulfilled by endoscopic
therapies such as endoscopic sleeve gastroplasty (ESG). Methods: In this case series, we report our preliminary experience of ESG in three obese patients.
We recorded baseline demographic data, total procedural time, adverse events, and
percentage total body weight loss (%TBWL) up to 20 weeks. Results: All three patients were male with a median age of 29 years (range 26–39) with a median
body mass index of 34.28 kg/m2 (range 32.60–37.13). A total of four full‑thickness
and additional three submucosal sutures were applied in each patient. There were no
adverse events. The median total procedural time was 105 min (range 90–150). All patients
were discharged within 48 h. The median percentage total body weight loss (%TBWL)
at 12 weeks was 12.02 (range 10.85–13.33) and at 16 weeks was 14.23 (range 13.84–14.62).
The maximum follow‑up so far is 20 weeks (one patient) with %TBWL of 16.38. Conclusion: In our preliminary experience, we conclude that ESG is safe, effective and requires
shorter hospital stay. In short‑term follow‑up, there is adequate weight loss without
major adverse events.
KEYWORDS
Endoscopic sleeve gastroplasty
-
endoscopic therapy
-
metabolic syndrome
-
obesity
-
weight loss
